- Condition: Hepatitis C, Chronic
Interventions: Drug: RO5024048; Drug: RO5024048; Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin [Copegus]; Drug: danoprevir; Drug: ritonavir
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified May 2012 - Conditions: Genotype 1 Chronic Hepatitis C; Treatment naïve With HCV-1/HIV-1 Coinfection; Treatment Experienced With HCV-1/HIV-1 Coinfection
Interventions: Drug: Telaprevir; Drug: Pegylated Interferon alfa-2a; Drug: Ribavirin
Sponsors: Tibotec BVBA; Tibotec BVBA
Not yet recruiting - verified January 2012 - Condition: HIV-1 Infection
Interventions: Drug: BMS-986001; Drug: BMS-986001; Drug: BMS-986001; Drug: Placebo matching with BMS-986001; Drug: Efavirenz; Drug: Lamivudine; Drug: Tenofovir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011 - Condition: Hepatitis C, Genotype 1
Interventions: Drug: BMS-790052 (Daclatasvir); Drug: Ribavirin; Drug: Peg-Interferon alfa 2a
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012 - Condition: Perimenopausal Depression
Intervention: Drug: Tibolone
Sponsors: The Alfred; The Alfred
Recruiting - verified January 2012 - Conditions: Human Immunodeficiency Virus (HIV); HIV Associated Neurocognitive Disorders (HAND)
Intervention: Drug: Maraviroc
Sponsors: St Vincent's Hospital, Sydney; Bruce Brew; ViiV Healthcare
Not yet recruiting - verified October 2011 - Conditions: Human Immunodeficiency Virus (HIV); HIV Associated Neurocognitive Disorders (HAND)
Intervention: Drug: Raltegravir
Sponsors: St Vincent's Hospital, Sydney; St Vincent's Hospital, Sydney; Merck
Not yet recruiting - verified October 2011 - Condition: HIV
Intervention:
Sponsors: St Vincent's Hospital, Sydney; St Vincent's Hospital, Sydney; ViiV Healthcare
Not yet recruiting - verified September 2011 - Condition: HIV-1-Associated Cognitive Motor Complex
Intervention:
Sponsors: Holdsworth House Medical Practice; Holdsworth House Medical Practice
Recruiting - verified November 2011 - Conditions: HIV-1 Infection; Cardiovascular Disease
Interventions: Other: Control; Other: Intervention Group
Sponsors: Holdsworth House Medical Practice; Holdsworth House Medical Practice
Recruiting - verified November 2011 - Condition: Human Papillomavirus
Intervention:
Sponsors: The Alfred; The Alfred; Merck
Recruiting - verified August 2011 - Condition: HIV
Intervention: Drug: Maraviroc
Sponsors: Kirby Institute; Kirby Institute; ViiV Healthcare; Pfizer
Recruiting - verified August 2011 - Condition: HIV Positive
Intervention: Drug: Vorinostat
Sponsors: Bayside Health; Bayside Health; Merck
Recruiting - verified June 2011 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir DF; Drug: cobicistat and atazanavir or cobicistat and darunavir
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: HIV-1
Interventions: Drug: Maraviroc; Drug: Emtricitabine/tenofovir
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2012 - Condition: Chronic Hepatitis B
Interventions: Drug: Tenofovir Disoproxil Fumarate, Peginterferon α-2a; Drug: Tenofovir Disoproxil Fumarate, Peginterferon α-2a; Drug: Tenofovir Disoproxil Fumarate; Drug: Peginterferon α-2a
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: HIV-1 Infections
Interventions: Drug: Darunavir; Drug: ritonavir; Drug: Darunavir; Drug: ritonavir
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Condition: HIV-1 Infection
Intervention: Drug: Rilpivirine
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified May 2012 - Conditions: HIV; Cardiovascular Disease
Interventions: Drug: raltegravir plus truvada; Drug: Darunavir, ritonavir, tenofovir/emtricitabine (Truvada)
Sponsors: St Vincent's Hospital, Sydney; St Vincent's Hospital, Sydney; Merck
Recruiting - verified September 2011 - Condition: HIV-1
Interventions: Drug: lersivirine; Drug: lersivirine; Drug: efavirenz; Drug: lersivirine; Drug: lersivirine; Drug: etravirine
Sponsors: Pfizer; Pfizer; ViiV Healthcare
Recruiting - verified May 2012 - Conditions: Infant, Premature, Diseases; Bronchopulmonary Dysplasia; Retinopathy of Prematurity; Infant, Newborn, Diseases; Infant, Very Low Birth Weight
Interventions: Procedure: Higher oxygen saturation target range (91%-95%); Procedure: Lower oxygen saturation (85%-89%)
Sponsors: University of Sydney; University of Sydney; University of Otago; University of Oxford; University of Pennsylvania; University of California, San Diego
Recruiting - verified August 2011 - Conditions: HIV Prevention; HIV Infections
Intervention: Drug: Raltegravir
Sponsors: St Vincent's Hospital, Sydney; St Vincent's Hospital, Sydney; Merck
Recruiting - verified August 2010 - Condition: Influenza
Intervention:
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health (NIH)
Recruiting - verified April 2012 - Conditions: Influenza; (Influenza A and Subtypes Such as H3N2 and 2009 H1N1 or Influenza B)
Intervention:
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health (NIH)
Recruiting - verified April 2012 - Condition: HIV Infections
Interventions: Drug: Efavirenz; Drug: Efavirenz
Sponsors: Kirby Institute; Kirby Institute
Recruiting - verified November 2011 - Condition: HIV Infection
Intervention: Drug: All licensed antiretroviral medications
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); Copenhagen HIV Programme (CHIP) -- Copenhagen, Denmark; Medical Research Council (MRC) Clinical Trials Unit -- London, United Kingdom; Kirby Institute; The Institute for Clinical Research at the Veterans Affairs Medical Center -- Washington, D.C., USA; French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); German Federal Ministry of Education and Research; NEAT - European AIDS Treatment Network; National Health and Medical Research Council, Australia; National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Mental Health (NIMH); National Institute of Neurological Disorders and Stroke (NINDS); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Abbott; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Merck; Tibotec Pharmaceutical Limited
Recruiting - verified April 2012 - Condition: HIV Infections
Intervention: Drug: Tipranavir
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Available - verified May 2012 - Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
 |
Join Clinical Trials in Montgomery,Alabama |
